​

Entrada Therapeutics (TRDA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Entrada Therapeutics Revenue Highlights

Latest Revenue (Y)

$210.78M

Latest Revenue (Q)

$20.56M

Main Segment (Y)

License

Entrada Therapeutics Revenue by Period

Entrada Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$210.78M63.38%
2023-12-31$129.01M100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

Entrada Therapeutics generated $210.78M in revenue during NA 2024, up 63.38% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Entrada Therapeutics Revenue by Quarter

DateRevenueChange
2025-03-31$20.56M-45.03%
2024-12-31$37.40M91.10%
2024-09-30$19.57M-79.33%
2024-06-30$94.69M60.17%
2024-03-31$59.12M41.27%
2023-12-31$41.85M-4.31%
2023-09-30$43.73M140.70%
2023-06-30$18.17M-28.07%
2023-03-31$25.26M100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

Entrada Therapeutics generated $20.56M in revenue during Q1 2025, up -45.03% compared to the previous quarter, and up 49.13% compared to the same period a year ago.

Entrada Therapeutics Revenue Breakdown

Entrada Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23
License$20.20M$139.00M

Entrada Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (100.00%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
License$900.00K$1.70M-$53.90M$70.90M$157.90M-$211.60M--
Upfront Payment Revenue-------$39.80M$14.63M-

Entrada Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: License (100.00%).

Entrada Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
TRDAEntrada Therapeutics$210.78M$20.56M
ENTAEnanta Pharmaceuticals$67.64M$18.31M
SGMOSangamo Therapeutics$57.80M$6.44M
OABIOmniAb$26.39M$4.15M
FHTXFoghorn Therapeutics$22.60M$7.56M
PYXSPyxis Oncology$16.15M-
IMRXImmuneering--
ZURAZura Bio--
CRBUCaribou Biosciences--
SAVACassava Sciences--
SGMTSagimet Biosciences--

TRDA Revenue FAQ

What is Entrada Therapeutics’s yearly revenue?

Entrada Therapeutics's yearly revenue for 2024 was $210.78M, representing an increase of 63.38% compared to 2023. The company's yearly revenue for 2023 was $129.01M, representing an increase of 100.00% compared to 2022. TRDA's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is Entrada Therapeutics’s quarterly revenue?

Entrada Therapeutics's quarterly revenue for Q1 2025 was $20.56M, a -45.03% decrease from the previous quarter (Q4 2024), and a -65.23% decrease year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $37.4M, a 91.10% increase from the previous quarter (Q3 2024), and a -10.63% decrease year-over-year (Q4 2023). TRDA's quarterly revenue for Q3 2024 was $19.57M, a -79.33% decrease from the previous quarter (Q2 2024), and a -55.25% decrease year-over-year (Q3 2023).

What is Entrada Therapeutics’s revenue growth rate?

Entrada Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.

What are Entrada Therapeutics’s revenue streams?

Entrada Therapeutics's revenue streams in c 24 are License

What is Entrada Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Entrada Therapeutics was License. This segment made a revenue of $20.2M, representing 100.00% of the company's total revenue.